We rank companies based on fund manager, research analyst and news sentiment
ACXP stock icon

Acurx Pharmaceuticals
ACXP

$2.13
18.89%
 

About: Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.

Employees: 4

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

143% more capital invested

Capital invested by funds: $1.32M [Q3] → $3.2M (+$1.88M) [Q4]

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

22% more funds holding

Funds holding: 18 [Q3] → 22 (+4) [Q4]

0.67% less ownership

Funds ownership: 6.75% [Q3] → 6.08% (-0.67%) [Q4]

81% less call options, than puts

Call options by funds: $29.9K | Put options by funds: $159K

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$12
463%
upside
Avg. target
$13.25
522%
upside
High target
$14
557%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Ed Arce
463%upside
$12
Buy
Maintained
19 Mar 2024
HC Wainwright & Co.
Ed Arce
557%upside
$14
Buy
Reiterated
28 Feb 2024
HC Wainwright & Co.
Ed Arce
557%upside
$14
Buy
Maintained
15 Dec 2023
HC Wainwright & Co.
Ed Arce
510%upside
$13
Buy
Reiterated
15 Nov 2023

Financial journalist opinion